Cipher Pharmaceuticals Inc (CPH) - Net Assets
Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) has net assets worth CA$132.84 Million CAD (≈ $96.09 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$153.39 Million ≈ $110.96 Million USD) and total liabilities (CA$20.55 Million ≈ $14.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Cipher Pharmaceuticals Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$132.84 Million |
| % of Total Assets | 86.6% |
| Annual Growth Rate | 7.93% |
| 5-Year Change | 223.97% |
| 10-Year Change | 599.54% |
| Growth Volatility | 159.72 |
Cipher Pharmaceuticals Inc - Net Assets Trend (2004–2025)
This chart illustrates how Cipher Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Cipher Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual net assets of Cipher Pharmaceuticals Inc from 2004 to 2025. For live valuation and market cap data, see Cipher Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$126.01 Million ≈ $91.16 Million |
+23.13% |
| 2024-12-31 | CA$102.34 Million ≈ $74.03 Million |
+27.10% |
| 2023-12-31 | CA$80.52 Million ≈ $58.25 Million |
+25.66% |
| 2022-12-31 | CA$64.08 Million ≈ $46.35 Million |
+64.74% |
| 2021-12-31 | CA$38.90 Million ≈ $28.14 Million |
+19.16% |
| 2020-12-31 | CA$32.64 Million ≈ $23.61 Million |
+16.53% |
| 2019-12-31 | CA$28.01 Million ≈ $20.26 Million |
+13.13% |
| 2018-12-31 | CA$24.76 Million ≈ $17.91 Million |
+7.95% |
| 2017-12-31 | CA$22.94 Million ≈ $16.59 Million |
+27.32% |
| 2016-12-31 | CA$18.01 Million ≈ $13.03 Million |
-66.80% |
| 2015-12-31 | CA$54.26 Million ≈ $39.25 Million |
+719.86% |
| 2014-12-31 | CA$6.62 Million ≈ $4.79 Million |
-81.82% |
| 2013-12-31 | CA$36.40 Million ≈ $26.33 Million |
+191.89% |
| 2012-12-31 | CA$12.47 Million ≈ $9.02 Million |
+34.02% |
| 2011-12-31 | CA$9.30 Million ≈ $6.73 Million |
-18.89% |
| 2010-12-31 | CA$11.47 Million ≈ $8.30 Million |
+9.52% |
| 2009-12-31 | CA$10.47 Million ≈ $7.58 Million |
-2.15% |
| 2008-12-31 | CA$10.71 Million ≈ $7.74 Million |
-32.38% |
| 2007-12-31 | CA$15.83 Million ≈ $11.45 Million |
-14.03% |
| 2006-12-31 | CA$18.41 Million ≈ $13.32 Million |
-3.91% |
| 2005-12-31 | CA$19.16 Million ≈ $13.86 Million |
-24.44% |
| 2004-12-31 | CA$25.36 Million ≈ $18.34 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cipher Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13178067574.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CA$99.93 Million | 79.30% |
| Common Stock | CA$27.81 Million | 22.07% |
| Other Comprehensive Income | CA$-9.50 Million | -7.54% |
| Other Components | CA$7.77 Million | 6.17% |
| Total Equity | CA$126.01 Million | 100.00% |
Cipher Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Cipher Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Antipa Minerals Ltd
AU:AZY
|
$297.75 Million |
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
$297.80 Million |
|
LIBERTY LAT.AMER.A DL-01
F:1LL
|
$297.88 Million |
|
MEDI ASSIST HEALTHCARE SERVICES LIMITED
NSE:MEDIASSIST
|
$297.90 Million |
|
Sarana Meditama Metropolitan
JK:SAME
|
$297.71 Million |
|
Hutchison Telecommunications (Australia) Ltd
AU:HTA
|
$297.71 Million |
|
Digital Imaging Technology INC
KQ:110990
|
$297.65 Million |
|
Jiangsu Fengshan Group Co Ltd
SHG:603810
|
$297.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cipher Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 102,343,000 to 126,014,254, a change of 23,671,254 (23.1%).
- Net income of 27,807,408 contributed positively to equity growth.
- Share repurchases of 5,475,196 reduced equity.
- Other comprehensive income increased equity by 17,315.
- Other factors increased equity by 1,321,727.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$27.81 Million | +22.07% |
| Share Repurchases | CA$5.48 Million | -4.34% |
| Other Comprehensive Income | CA$17.32K | +0.01% |
| Other Changes | CA$1.32 Million | +1.05% |
| Total Change | CA$- | 23.13% |
Book Value vs Market Value Analysis
This analysis compares Cipher Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.39x to 3.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | CA$1.21 | CA$16.21 | x |
| 2005-12-31 | CA$0.90 | CA$16.21 | x |
| 2006-12-31 | CA$0.78 | CA$16.21 | x |
| 2007-12-31 | CA$0.66 | CA$16.21 | x |
| 2008-12-31 | CA$0.45 | CA$16.21 | x |
| 2009-12-31 | CA$0.44 | CA$16.21 | x |
| 2010-12-31 | CA$0.48 | CA$16.21 | x |
| 2011-12-31 | CA$0.38 | CA$16.21 | x |
| 2012-12-31 | CA$0.51 | CA$16.21 | x |
| 2013-12-31 | CA$1.41 | CA$16.21 | x |
| 2014-12-31 | CA$0.26 | CA$16.21 | x |
| 2015-12-31 | CA$2.06 | CA$16.21 | x |
| 2016-12-31 | CA$0.67 | CA$16.21 | x |
| 2017-12-31 | CA$0.86 | CA$16.21 | x |
| 2018-12-31 | CA$0.92 | CA$16.21 | x |
| 2019-12-31 | CA$1.04 | CA$16.21 | x |
| 2020-12-31 | CA$1.19 | CA$16.21 | x |
| 2021-12-31 | CA$1.45 | CA$16.21 | x |
| 2022-12-31 | CA$2.50 | CA$16.21 | x |
| 2023-12-31 | CA$3.17 | CA$16.21 | x |
| 2024-12-31 | CA$4.17 | CA$16.21 | x |
| 2025-12-31 | CA$4.85 | CA$16.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cipher Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 54.17%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.24x
- Recent ROE (22.07%) is above the historical average (-12.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -39.17% | -39.08% | 0.79x | 1.28x | CA$-12.47 Million |
| 2005 | -38.23% | -1132.76% | 0.03x | 1.16x | CA$-9.24 Million |
| 2006 | -56.20% | -1328.53% | 0.04x | 1.05x | CA$-12.19 Million |
| 2007 | -41.11% | -1197.96% | 0.03x | 1.19x | CA$-8.09 Million |
| 2008 | -24.79% | -209.33% | 0.09x | 1.26x | CA$-3.72 Million |
| 2009 | -24.75% | -85.40% | 0.21x | 1.35x | CA$-3.64 Million |
| 2010 | 0.49% | 1.04% | 0.33x | 1.41x | CA$-1.09 Million |
| 2011 | -24.33% | -64.75% | 0.24x | 1.54x | CA$-3.19 Million |
| 2012 | 20.51% | 30.08% | 0.39x | 1.77x | CA$1.31 Million |
| 2013 | 64.42% | 92.43% | 0.49x | 1.43x | CA$19.81 Million |
| 2014 | -72.91% | -58.42% | 0.74x | 1.68x | CA$-5.49 Million |
| 2015 | 3.26% | 5.14% | 0.31x | 2.02x | CA$-3.66 Million |
| 2016 | -217.33% | -96.09% | 0.53x | 4.30x | CA$-40.95 Million |
| 2017 | 19.20% | 10.92% | 0.64x | 2.75x | CA$2.11 Million |
| 2018 | 2.19% | 2.39% | 0.41x | 2.25x | CA$-1.93 Million |
| 2019 | 11.57% | 14.44% | 0.48x | 1.66x | CA$440.90K |
| 2020 | 13.94% | 21.05% | 0.49x | 1.36x | CA$1.28 Million |
| 2021 | 19.94% | 35.36% | 0.42x | 1.33x | CA$3.87 Million |
| 2022 | 41.57% | 128.83% | 0.28x | 1.15x | CA$20.23 Million |
| 2023 | 25.31% | 96.32% | 0.25x | 1.07x | CA$12.33 Million |
| 2024 | 11.28% | 34.60% | 0.21x | 1.59x | CA$1.31 Million |
| 2025 | 22.07% | 54.17% | 0.33x | 1.24x | CA$15.21 Million |
Industry Comparison
This section compares Cipher Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $790,716,963
- Average return on equity (ROE) among peers: -56.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cipher Pharmaceuticals Inc (CPH) | CA$132.84 Million | -39.17% | 0.15x | $297.74 Million |
| Aurora Cannabis Inc (ACB) | $1.69 Million | -10.52% | 0.00x | $171.89 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-6.45 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $3.46 Million | -426.03% | 4.09x | $12.28 Million |
| Avant Brands Inc (AVNT) | $32.85 Million | -68.65% | 0.81x | $6.98 Million |
| Bausch Health Companies Inc (BHC) | $5.94 Billion | 40.44% | 5.31x | $1.87 Billion |
| CanadaBis Capital Inc (CANB) | $2.63 Million | 23.10% | 4.88x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $266.93 Million | -39.33% | 0.51x | $12.41 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $76.24 Million | -32.43% | 0.15x | $118.76 Million |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more